Canadian Markets open in 2 hrs 50 mins

Cytori Therapeutics, Inc. (CYTX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.4749-0.0050 (-1.0419%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close0.4799
Bid0.4750 x 3000
Ask0.4980 x 900
Day's Range0.4300 - 0.4949
52 Week Range0.4100 - 2.2900
Avg. Volume698,858
Market Cap15.42M
PE Ratio (TTM)-0.39
EPS (TTM)-1.23
Earnings DateMar 3, 2017 - Mar 6, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • GlobeNewswire14 hours ago

    Cytori Therapeutics Announces Inducement Grants for New Employees

    SAN DIEGO, July 25, 2017-- Cytori Therapeutics, Inc., announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on July 19, 2017 to four new ...

  • Accesswire23 hours ago

    Today's Research Reports on Stocks to Watch: Cytori Therapeutics and Novavax

    NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Cytori Therapeutics saw its shares crushed on Monday, with the stock losing 56% at the close. Investors were disappointed with the company's preliminary data ...

  • SmarterAnalyst2 days ago

    Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR)

    Cytori Therapeutics Inc: Should You Catch This Falling Knife? Cytori Therapeutics Inc (NASDAQ:CYTX) shares are crashing over 60% in Monday's trading session, after the biotech company disclosed that its pivotal STAR study assessing Habeo Cell Therapy for the treatment of scleroderma failed to achieve its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48. Kolbert noted, "The totality of the data combined with the investigator comments matter and suggest to us that there maybe a window for approval based on the current data set and/or a small bridging study.